These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 19025367)

  • 21. Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure.
    Ter Heine R; Huitema AD; Jansen RS; Smits PH; van Gorp EC; Wagenaar JF; Beijnen JH; Mulder JW
    Antivir Ther; 2009; 14(2):299-301. PubMed ID: 19430105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rethinking recycling nucleoside reverse transcriptase inhibitors in HIV treatment: learning from dual therapy studies.
    Ripamonti D; Zazzi M
    AIDS; 2018 Apr; 32(7):835-840. PubMed ID: 29424781
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility.
    Ehteshami M; Götte M
    AIDS Rev; 2008; 10(4):224-35. PubMed ID: 19092978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin resistance among HIV-infected patients: unraveling the mechanism.
    Hadigan C
    Clin Infect Dis; 2005 Nov; 41(9):1341-2. PubMed ID: 16206113
    [No Abstract]   [Full Text] [Related]  

  • 26. Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study.
    Sarfo FS; Bibby DF; Schwab U; Appiah LT; Clark DA; Collini P; Phillips R; Green I; Dittmar MT; Chadwick DR
    J Antimicrob Chemother; 2009 Sep; 64(3):667-9. PubMed ID: 19549668
    [No Abstract]   [Full Text] [Related]  

  • 27. Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy.
    Arastéh K; Rieger A; Yeni P; Pozniak A; Boogaerts G; van Heeswijk R; de Béthune MP; Peeters M; Woodfall B
    Antivir Ther; 2009; 14(5):713-22. PubMed ID: 19704175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir.
    Theys K; Vercauteren J; Abecasis AB; Libin P; Deforche K; Vandamme AM; Camacho R
    Infect Genet Evol; 2009 Jul; 9(4):683-8. PubMed ID: 19038365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients.
    Wirden M; Lambert-Niclot S; Marcelin AG; Schneider L; Ait-Mohand H; Brunet C; Angleraud F; Amard S; Katlama C; Calvez V
    AIDS; 2009 Jan; 23(1):95-9. PubMed ID: 19050391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The brightening future of HIV therapeutics.
    Greene WC
    Nat Immunol; 2004 Sep; 5(9):867-71. PubMed ID: 15334078
    [No Abstract]   [Full Text] [Related]  

  • 31. Top stories of 2008. Antiretroviral rollout--successes and challenges.
    Friedland GH
    AIDS Clin Care; 2009 Jan; 21(1):5. PubMed ID: 19219959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First-line antiretroviral therapy in resource-limited settings: time to reconsider?
    Adlington R; Richens J; Shahmanesh M
    J Infect Dis; 2009 May; 199(9):1407; author reply 1407-8. PubMed ID: 19358673
    [No Abstract]   [Full Text] [Related]  

  • 34. Apricitabine continues to show good results.
    Dalton P
    Proj Inf Perspect; 2008 Sep; (46):12. PubMed ID: 19043879
    [No Abstract]   [Full Text] [Related]  

  • 35. Anti-HIV agents. Non-nukes and the brain.
    TreatmentUpdate; 2007 Jan; 19(1):6. PubMed ID: 17390479
    [No Abstract]   [Full Text] [Related]  

  • 36. RDEA study supports development of new NNRTI.
    Proj Inf Perspect; 2008 Dec; (47):11-2. PubMed ID: 19230233
    [No Abstract]   [Full Text] [Related]  

  • 37. Resistance mutations in HIV-1 infected pregnant women and their infants receiving antiretrovirals to prevent HIV-1 vertical transmission in China.
    Han J; Wang L; Jiang Y; Zhang Q; Fang L; Yao J; Wang Q
    Int J STD AIDS; 2009 Apr; 20(4):249-54. PubMed ID: 19304969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors.
    Bracciale L; Colafigli M; Zazzi M; Corsi P; Meraviglia P; Micheli V; Maserati R; Gianotti N; Penco G; Setti M; Di Giambenedetto S; Butini L; Vivarelli A; Trezzi M; De Luca A
    J Antimicrob Chemother; 2009 Sep; 64(3):607-15. PubMed ID: 19608581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. To nuke, or not to nuke?
    Proj Inf Perspect; 2007 Apr; (43):1-3. PubMed ID: 17684823
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA notifications. FDA approves generic stavudine.
    AIDS Alert; 2009 Mar; 24(3):34. PubMed ID: 19441156
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.